Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Zegalogue (dasiglucagon) is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Dasiglucagon significantly reduced recovery time of blood glucose by increasing levels by 20.0 mg/dL from baseline, showing superior effectiveness compared to placebo (PMD: -23.30%, 95% CI: 23.97 to 22.63, p < 0.00001) and oral glucose (MD: -15.00 minutes; 95% CI: -20.33 to -9.67; p < 0.00001), but no statistically significant difference compared to glucagon (MD: -0.76 minutes; 95% CI: -2.19 to 0.66; p = 0.29).
• In studies focusing on patients with Type 1 Diabetes Mellitus (T1DM), dasiglucagon demonstrated statistically significant improvement in glucose recovery time compared to glucagon in one study (PMD: 1.08%, 95% CI: 1.96 to 0.21, p = 0.02), but another study found no significant difference in time to recovery (MD: -0.76 minutes; 95% CI: -2.19 to 0.66; p = 0.29).
• The effectiveness of dasiglucagon was consistently superior to placebo and oral glucose in reducing time to recovery, with no significant safety concerns noted in the studies focused on T1DM patients, and the safety profile was comparable to glucagon.
• The safety outcomes of dasiglucagon were comparable to native glucagon, with no significant safety concerns or adverse effects explicitly noted in patients with Type 1 Diabetes Mellitus (T1DM).
• No specific safety comparisons with placebo or oral glucose were highlighted, and no significant adverse effects were reported in the studies.
• There is no population types or subgroups information available in the reviewed studies.